Alnylam Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ALNY, updated each market day.
ALNY AI Sentiment
AI sees no strong directional signal for Alnylam Pharmaceuticals, Inc. stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Sector
Exchange
Market Cap
$41,868,343,878
Cap Tier
Employees
2,500
Headquarters
CAMBRIDGE, MA
Listed Since
May 28, 2004
Website
ALNY Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ALNY Volatility
Alnylam Pharmaceuticals, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
